Longpan Investment
VC Fund
Beijing, China
Longpan Investment is an investment firm.
- Total investments:
- 44
- Last investment:
- Lead investor:
- 55%
Last updated:
For AI agents: llms.txt
Industries Longpan Investment invests in
Stages Longpan Investment invests in
Countries Longpan Investment invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $14M–$60M
- Series A
- $14M–$32M
- Series B
- $14M–$37M
Investment Focus
Industry
- Health Care 18 (41%)
- Medical 17 (39%)
- Biotechnology 17 (39%)
- Biopharma 9 (20%)
- Pharmaceutical 9 (20%)
Stage
- Series A 21 (48%)
- Seed 7 (16%)
- Series B 7 (16%)
- Angel 2 (5%)
- Series C 1 (2%)
Country
- China 32 (73%)
- United States 1 (2%)
- Cayman Islands 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Wang Ji
Vice President
|
Vice President | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Jingling Zhikang
|
Jingling Zhikang is technology company specializing in the intersection of medical rehabilitation, robotics, and embodied artificial intelligence. The company focuses on developing intelligent rehabilitation bionic hands and upper-limb prosthetics. | $14.8M / Angel / Jul 24, 2026 | |
|
Hanyue New Materials
|
Hanyue Advanced Materials is a high-tech company that specializes in single-use biopharmaceutical solutions. | Seed / Jul 02, 2026 | |
| Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs. | Series A / Jun 26, 2026 | ||
| Qinghui Liannuo is a scientific and technological innovation enterprise that transforms Tsinghua University's achievements in the research and development and application of immunotherapy technology. Actively promote the development of the γδ-T cell immunotherapy industry. Committed to bringing good news to patients with refractory andrecurrent solid tumors and hematomas. | $29.5M / Series A / Jun 09, 2026 | ||
| Bodie Hekang is a biopharmaceutical services company dedicated to advancing therapies for autoimmune and inflammatory diseases. Combining translational research, preclinical development, and clinical support, the company specializes in engineering and developing regulatory T cell (Treg) immunotherapies designed to restore immune tolerance andreduce pathological inflammation. Bodie Hekang partners with academic institutions, biotech firms, and pharmaceutical companies to provide end-to-end services that include target validation, cell manufacturing process development, potency and safety testing, and regulatory strategy support. Its multidisciplinary team of immunologists, cell biologists, and clinical development experts focuses on innovative approaches to enhance Treg stability, specificity, and functionality, aiming to translate promising laboratory findings into scalable, clinically viable treatments for conditions such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus. | Series A / May 21, 2026 | ||
|
Maibozhixing
|
MaiboZhixing is an innovative company focused on antibody drug development and dedicated to developing next-generation antibody therapies for the treatment of inflammatory and autoimmune diseases. | $14.5M / Angel / Mar 23, 2026 | |
|
Baiyi Pharmaceutical
|
Baiyi Pharmaceutical is a research-driven pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for neurological diseases, aiming to address unmet medical needs and improve patient outcomes. | $14.3M / Seed / Jan 13, 2026 | |
| Bohui Bio is an immune disease research and development company. | $14.2M / Series A / Dec 12, 2025 | ||
| Best-Link Bioscience is a high-tech enterprise engaged in innovative drug research and development, focusing on cutting-edge scientific discovery, advanced therapeutic technologies, and the creation of novel medicines to address unmet clinical needs and improve patient outcomes worldwide. | $36.7M / Series B / Dec 11, 2025 | ||
| Sanctuary Bio is a DNA damage repair drug developer, focusing on the field of DNA damage repair. | $14.1M / Series A / Dec 08, 2025 | ||
| See all 44 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Longpan Investment invest in?
Longpan Investment invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Seed stage. Most of the 44 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Longpan Investment's check size?
Longpan Investment typically joins rounds of $14M–$60M at Seed, $14M–$32M at Series A and $14M–$37M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Longpan Investment participates in.
How do I contact Longpan Investment?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Longpan Investment?
The team at Longpan Investment includes Wang Ji (Vice President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
